Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received national regulatory approval in Finland.
Following the regulatory approval of Toctino in Finland, Basilea will submit a pricing and reimbursement dossier to the Finnish authorities.
Toctino (alitretinoin) was developed by Basilea Pharmaceutica International.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.